PeterWesterveltMD

Oncology • Brunswick, ME

Professor, Internal Medicine, Washington University School of Medicine

Join to view full profile

Dr. Westervelt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Westervelt's full profile

Already have an account?

Office
329 Maine St
Brunswick, ME 04011
Phone+1 207-373-2266

Fax+1 314-454-5902

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 1994 - 1999
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1992 - 1994
Washington University in St. Louis School of MedicineClass of 1992

Certifications & Licensure

MA State Medical License 2001 - 2026
ME State Medical License 2023 - 2025
MO State Medical License 2006 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML Start of enrollment: 2009 Oct 01
Completed
Phase 2
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2009 May 05
Active, not recruiting
Phase 2
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) Start of enrollment: 2009 Apr 01
Completed
Phase 2
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2012 May 14
Completed
Phase 1, Phase 2
Selecting a Favorable KIR Donor in Unrelated HCT for AML Start of enrollment: 2011 Jun 01
Completed
Not Applicable
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease Start of enrollment: 2011 Mar 01
Completed
Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Roles: Principal Investigator, Contact
Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant Start of enrollment: 2012 Apr 01
Completed
Phase 1
A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL Start of enrollment: 2012 Mar 01
Terminated
Phase 3
Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen Start of enrollment: 2011 Nov 01
Completed
Phase 2
The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies. Start of enrollment: 2012 Jul 01
Terminated
Phase 2
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation Start of enrollment: 2013 Feb 25
Completed
Phase 1
Geriatric Assessments in Senior Adults With Multiple Myeloma Start of enrollment: 2012 Sep 01
Completed
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation Start of enrollment: 2013 Apr 15
Terminated
Phase 1, Phase 2
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Aug 11
Terminated
Phase 1, Phase 2
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma Start of enrollment: 2014 Mar 19
Completed
Phase 2
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102) Start of enrollment: 2013 Dec 16
Completed
Phase 2
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Feb 28
Terminated
Phase 1
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Start of enrollment: 2014 Aug 20
Completed
Phase 2
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation Start of enrollment: 2015 Jan 20
Terminated
Phase 2
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma Start of enrollment: 2015 Feb 20
Completed
Phase 1
CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia Start of enrollment: 2017 Apr 07
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

21 citations
Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.
Lawrence Wayne Liu, Alicia Yn, Feng Gao, Marissa Olson, Mallory Crain
Transplantation and Cellular Therapy. 2022-08-01
86 citations
Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML.
Terrence N. Wong, Christopher A. Miller, Jeffery M. Klco, Allegra A. Petti, Ryan Demeter
Blood. 2016-02-18
134 citations
Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential.
Terrence N. Wong, Christopher A. Miller, Matthew Rm Jotte, Nusayba Bagegni, Jack Baty
Nature Communications. 2018-01-31

Journal Articles

Exome Analysis of Treatment‐Related AML After APL Suggests Secondary Evolution
John S Welch, Eric J Duncavage, Meagan A Jacoby, Peter Westervelt, Lukas D Wartman, British Journal of Haematology
Bone Marrow Biopsy Needle Type Affects Core Biopsy Specimen Length and Quality and Aspirate Hemodilution
Anjum Hassan, Peter Westervelt, Friederike Kreisel, American Journal of Clinical Pathology
Secondary Acute Lymphoblastic Leukemia, a Retrospective Analysis from Washington University and Meta-Analysis of Published Data
Francesca Ferraro, Peter Westervelt, John F Dipersio, Armin Ghobadi, Leukemia Research
Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell Transplantation
M A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature
Join now to see all

Abstracts/Posters

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDSClinically Relevant Abst...
Peter Westervelt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Molecular Basis of Long First Remissions in Normal Karyotype AML Patients
Peter Westervelt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide
Peter Westervelt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Tr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)Clinicall...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Evidence for Complete Mutation Clearance in Normal Karyotype AML Patients with Very Long (> 5 years) Remissions after Chemotherapy Alone
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

Secondary Acute Lymphoblastic Leukemia, a Retrospective Analysis from Washington University and Meta-Analysis of Published DataAugust 2018

Press Mentions

$15 Million Supports Quest for Personalized Leukemia TherapiesAugust 21st, 2019
CX-01 Heparin Derivative Investigated for Older Patients with AMLJune 14th, 2019
$Amphivena Demonstrates at EHA First Human Proof-of-Concept for AMV564 in Relapsed/Refractory AML$
Amphivena Demonstrates at EHA First Human Proof-of-Concept for AMV564 in Relapsed/Refractory AMLJune 15th, 2018
Join now to see all

Grant Support

Clinical DatabaseNational Cancer Institute2008–2012
Sargrastim And Plerixafor Vs. Filgrastim For Allogeneic Stem Cell MobilizationNational Heart, Lung, And Blood Institute2011
Developmental Targeting--Pml Rara Expression In VivoNational Heart, Lung, And Blood Institute2001–2003
Developmental Targeting--Pml Rara Expression In VivoNational Heart, Lung, And Blood Institute1999–2001